ImmunoChina
艺妙神州
ImmunoChina
Biotech/Healthcare
Yimiao Shenzhou, founded in 2015, is an innovative biopharmaceutical company dedicated to applying gene and cell therapy technologies to the treatment of malignant tumors. The company has domestically leading R&D capabilities in CAR-T cell therapy drugs.
Latest round: Series D Extension+ (2023)
Source: ChinaBulls — chinabulls.com
Last updated 2023-05-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.